Background: Many patients are diagnosed with hypertension each year, making rapid and effective control of blood pressure (BP) crucial. Appropriate first-line treatment is important, and special attention should be paid to the positive effects of lowering BP early. Perindopril 3.5 mg/amlodipine 2.5 mg (P3.5/A2.5) is a single-pill combination suitable for first-line use. The doses of each component of the single-pill combination were selected for a first-line setting.
INTRODUCTION
T he high prevalence of hypertension [1] and its associated high risk of morbidity and mortality [2] [3] [4] underscore the need for better strategies to prevent, detect and treat hypertension and hence to reduce cardiovascular outcomes and improve survival -the ultimate goal of antihypertensive treatment [5] . However, despite some improvement [6] [7] [8] [9] [10] [11] , hypertension control worldwide remains far from optimal [6, [9] [10] [11] [12] [13] [14] [15] [16] , underlining the necessity for improved strategies for more efficacious and faster achievement of target blood pressure (BP) levels. Prior to the most recent hypertension guidelines produced in the United States [17] , hypertension had three grades of severity within the population, with most hypertensive patients diagnosed with grade 1 hypertension (SBP 140-159 mmHg and/or DBP 90-99 mmHg) [18, 19] . This usually progresses to grade 2 or 3 hypertension if left untreated or if inadequately treated [20] .
In recent years, several advances have been made in the therapeutic management of hypertension. First, the combination of agents from two or three different antihypertensive classes is frequently used in the treatment of severe hypertension to enhance the BP-lowering effect via complementary and synergistic mechanisms of action [21, 22] . Second, antihypertensive drugs are now routinely combined into a single tablet to simplify treatment and improve compliance [19, 23] . Third, the combination of lower doses of antihypertensive drug components with good safety profiles has been considered for grade 1 hypertensive patients [24] . Lastly, as two or more agents have been found to be necessary in the majority of hypertensive individuals to reach current BP targets, two-drug combinations have been proposed as an initial treatment strategy to allow for faster BP reduction compared with initial monotherapy followed by the subsequent addition of one or more antihypertensive drugs [25] [26] [27] [28] [29] [30] [31] . Moreover, with the combined use of antihypertensive drugs that act via more than one mechanism from the outset, patients demonstrate better long-term adherence to treatment and overall BP control as well as enhanced cardiovascular protection, as seen in observational studies [25] . These advantages may extend to the overall hypertensive population, regardless of the grade of hypertension. In a matched cohort study by Gradman et al. [27] , early use of combination treatment was associated with a higher percentage of patients reaching the BP targets as well as a greater reduction in cardiovascular outcomes, over a period of almost 2 years, compared with delayed use of combination treatment. These findings suggest that routine initial combination therapy may be a superior treatment strategy for a large segment of the hypertensive population.
Combining a renin-angiotensin system (RAS) inhibitor with a calcium channel blocker (CCB) is one of the standard combinations of therapy recommended in clinical guidelines [19, 32, 33] , and one that reportedly may afford greater cardioprotection than monotherapy [23, 34] . As part of a development programme, three randomized controlled trials (RCTs) investigated the efficacy and tolerability of a new single-pill combination of the angiotensin-converting enzyme (ACE) inhibitor, perindopril, and the CCB, amlodipine [35] [36] [37] . The two drugs have complementary modes of action and have been shown to provide cardiovascular protection in hypertensive patients [38] . The objective of the development programme was to create a single-pill combination suitable for first-line use with a BP-lowering effect that was at least equivalent to that of amlodipine 5 mg, but with a better tolerability profile -in particular, associated with less peripheral oedema. The doses of each component of the single-pill combination were selected for use in a first-line setting.
Here we present the results from a combined analysis of these three RCTs. The purpose of the combined analysis was to evaluate whether the perindopril 3.5 mg/amlodipine 2.5 mg (P3.5/A2.5) combination used as first-line treatment was more effective at lowering BP than standard-dose RASinhibitor monotherapies after 1 month of treatment.
METHODS
Individual patient data from the three RCTs that evaluated the efficacy of P3.5/A2.5 versus RAS-inhibitor monotherapies in patients with hypertension [35] [36] [37] were used to perform a combined analysis. The RAS-inhibitor monotherapies were perindopril 5 mg, irbesartan 150 mg and valsartan 80 mg, which are standard doses for a first-line setting. The primary efficacy outcome was change in supine SBP and DBP from baseline after 1 month of treatment. Emergent adverse events, including serious adverse events (SAEs), were also measured. Further details of the three RCTs are shown in Table 1 .
Trial databases were pooled and statistical analyses were performed using SAS, version 9.2 (SAS Institute Inc., Cary, North Carolina, USA). All patients randomized to either P3.5/A2.5 or RAS-inhibitor monotherapies, who had taken at least one dose of trial drug and had supine BP readings at baseline and at 1 month, were included in the combined analysis based on the intention-to-treat principle. A meta-analytic approach based on an analysis of covariance (ANCOVA) with treatment, baseline and country as fixed effects was performed on individual patient data. The between-group difference estimate (P3.5/A2.5 without RAS monotherapies), as well as associated 95% confidence intervals and P values, were provided. The statistical heterogeneity between studies was tested with a Cochran Q test. Inconsistencies between the trials were assessed by the I 2 indicator [39] . The primary analysis was conducted via a random-effects model, which took into account fluctuations in treatment effect between trials. The fixed effect model as well as the analyses on values under treatment at 1 month (random and fixed models) were used as sensitivity analyses. Emergent adverse events for both groups were compared using a Fisher's exact test in the safety-set population.
RESULTS
Of the 6625 patients randomized in the three RCTs, the current combined analysis included the 5496 patients randomized in the groups of interest, that is, in the P3.5/ A2.5 or RAS-inhibitor monotherapy groups and having an SBP assessment at baseline and at month 1, according to an intention-to-treat approach. Of these, 2729 were treated with P3.5/A2.5 and 2767 were treated with RAS-inhibitor monotherapies. The baseline characteristics of the two groups were similar ( Table 2) .
After 1 month of treatment, BP levels were significantly lower in patients treated with P3.5/A2.5 versus RAS-inhibitor monotherapies within each study ( Table 3) .
The estimated treatment differences for each trial are shown in Fig. 1 . Overall, treatment with P3.5/A2.5 was associated with a significantly lower SBP and DBP after 1 month of treatment compared with RAS-inhibitor monotherapies. Estimated treatment differences in the change in BP from baseline to month 1 were as follows: SBP À2.36 mmHg [95% confidence interval (CI) À3.83 to À0.89], P ¼ 0.002]; DBP À1.25 mmHg (95% CI À2.12 to À0.38, P ¼ 0.005) (Fig. 1) . Heterogeneity in effect sizes achieved in the two treatment groups for SBP and DBP was Data from [35] [36] [37] . BP, blood pressure; Irb, irbesartan; P3.5/A2.5, perindopril 3.5 mg/amlodipine 2.5 mg; P5, perindopril 5 mg; Val, valsartan. a P value from Generalized Linear Model adjusted on baseline, centre or country as well as, for P3.5/A2.5 versus Irb, age and diabetes.
First-line treatment in hypertension substantial (I 2 ¼ 67 and 68%, respectively). Similar results were achieved with the sensitivity analyses (data not shown).
The proportion of patients who experienced emergent adverse events and SAEs during 1 month of treatment was similar for both treatment groups (Table 4) . A significantly higher proportion of patients treated with P3.5/A2.5 experienced a cough, a known side effect of perindopril, compared with RAS-inhibitor monotherapies (4.5 versus 1.0%, P < 0.001). Compared with P3.5/A2.5, a significantly higher proportion of patients treated with RAS-inhibitor monotherapies experienced headaches (2.1 versus 3.0%, P ¼ 0.040) and diarrhoea (0.3 versus 0.8%, P ¼ 0.011). SAEs were reported only in a small proportion of patients, in both the groups treated with P3.5/A2.5 and the group treated with RAS-inhibitor monotherapies (0.8 versus 1.2%, P ¼ 0.081). SAE frequency did not exceed 0.30% in any of the SAE subgroups. No significant difference in SAEs was observed between the two treatment groups in any system organ class, with the exception of nervous system disorders for which results favoured the P3.5/A2.5 group over the RAS monotherapy group (P ¼ 0.008). No deaths were reported in either treatment groups.
DISCUSSION
Overall, results from this combined analysis of three RCTs demonstrated that, after 1 month of treatment, the P3.5/ A2.5 combination was statistically significantly better at lowering BP compared with RAS-inhibitor monotherapies, with similar tolerability. This beneficial effect was observed not only in patients with mild-to-moderate hypertension without complications [35] , but also in higher risk hypertensive patients [36, 37] .
A previous meta-analysis of 68 RCTs demonstrated that effective BP-lowering treatment positively impacted hard endpoints in patients for all grades of hypertension. The results indicated that using BP-lowering treatment in grade 1 hypertensive patients and reducing SBP/DBP levels to less than 140/90 mmHg significantly reduced the risk of stroke, coronary events and death [40, 41] . Gradman et al. [27] have emphasized that a rapid achievement of BP targets is key to 
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-8 -6 -4 -2 0 2 4 6 8 FIGURE 1 Estimated treatment differences between the perindopril 3.5 mg/amlodipine 2.5 mg combination and RAS-inhibitor monotherapies: meta-analysis of the data at month 1 [35] [36] [37] . CI, confidence interval; DBP, diastolic blood pressure; P3.5/A2.5, perindopril 3.5 mg/amlodipine 2.5 mg; RAS, renin-angiotensin system; SBP, systolic blood pressure.
reducing the risk of cardiovascular events. The ability of P3.5/A2.5 to significantly reduce BP levels within a month of treatment may thus have long-term beneficial effects in terms of cardiovascular risk reduction. However, additional investigations are required to establish whether the reduction in BP levels with P3.5/A2.5 has a long-term impact on cardiovascular events. In addition, it has been established that early reductions in BP levels can improve patient satisfaction and adherence to treatment. Lack of adherence in the long term is a common challenge, with half of all patients initiated on hypertensive treatments discontinuing within the first year [42] [43] [44] . Therefore, selection of a first-line antihypertensive regimen with good efficacy and tolerability levels can positively influence both treatment adherence and persistence [23, 45, 46] . Overall, P3.5/A2.5 had a good tolerability profile, which is consistent with the known safety profiles of the individual components. This was expected, as the P3.5/A2.5 dosages had been optimized for a first-line setting.
In conclusion, the present analysis shows that the new P3.5/A2.5 combination is suitable for use as a first-line treatment in patients with hypertension, compared with RAS-inhibitor monotherapies. Reducing BP levels within a month of treatment would help to improve patient adherence, possibly leading to additional long-term benefits including a reduced risk of cardiovascular events. First-line treatment in hypertension
